News

Substantial data packages on lead compounds MOR202 and MOR208.

Orphan drug designation in the European Union to treat advanced-stage glaucoma.

Approval to commence a Phase I/II clinical trial in the US with stem cell therapy candidate for RP.

Chemists have discovered a broad and strikingly inexpensive method for synthesizing “amines,” a class of organic compounds prominent in drugs and other modern products.

Body builders have it right: vitamin E does help build strong muscles, and scientists appear to have figured out one important way it does it.

This is the first time Organovo’s technology is being used within the beauty industry.

Current methods for producing nanofibers are incredibly costly and therefore limit accessibility, this new study opens the door to cheap, mass produced nanofibers.

Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.

Many affected individuals still suffer with progressive joint damage, despite treatment. This study has discovered a new treatment target which could open a door to preventing this ongoing damage.

Alliance establishes SCIEX and Hepregen as a one-stop solution provider for drug metabolism investigators.